JHX – N.V.Credit Suisse rates the stock as Outperform

By Broker News | More Articles by Broker News

Further input cost reductions strengthen FY20/21 expectations. Positive end market data and early US reporting commentary leads Credit Suisse to increase North American earnings estimates by 2% for FY20 and 6% for FY21.

In Europe, Fermacell appears to be a better quality business than the broker previously thought, with a more expansive product range and less chance of encroachment by competitors.

The company’s second quarter results are scheduled for November 7. Outperform rating maintained. Target rises to $28.90 from $23.70.

Sector: Materials.

Target price is $28.90.Current Price is $25.05. Difference: $3.85 – (brackets indicate current price is over target). If JHX meets the Credit Suisse target it will return approximately 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →